INVESTOR LUNCH
July 17, 2025 | Brickell, Miami
Luncheon Presentation - Brickell, Miami
PRESENTED BY:
Forcoda Ventures, in collaboration with WallStreet Research, is hosting a private investor luncheon in Miami on July 17.
LifePulse Corporation – a medtech company with a breakthrough PEF-based cancer treatment device that’s already making waves in veterinary oncology.
This is your chance to meet the founder, join one-on-one sessions, and get access to their Series A round – before a potential IPO or acquisition.
The event will be held in Brickell, Miami’s premier steakhouse (location will be shared with registered investors).
It’s exclusive to accredited investors, family offices, and select VC funds.
Join us for a private investor luncheon July 17th at Fleming’s Prime Steakhouse in Miami from 11:30 am to 3:00 pm. One-on-One’s will be available at each event. HNW accredited investors, family offices, fund managers and VC firms only. Consider Investing in the Future of an extremely promising medical device company LifePulse Corporation. RSVP to Alan Stone – 310-909-4134 (text) alanstone2@gmail.com or on link below.
Company: We’re excited to introduce LifePulse Corporation based in Tampa Florida.
The Problem
Over $57 billion is wasted annually on treating side effects and failed cancer therapies, impacting 2 million newly diagnosed cancer patients in the U.S. alone because existing treatments harm healthy cells and lack precise, targeted delivery.
The Solution
LifePulse delivers the scalable, next-gen electroporation technology for oncology driving targeted therapy into cancer cells, improving patient outcomes, and accessing a $150B market by solving inefficiencies in existing cancer treatments.
Presentation by: Gary Strange Founder, Chairman and Franck Carlier Chief Executive Officer
Mr. Strange has more than 20 years experience in quantitative modeling, valuation and strategic planning. He also has an extensive background in financing having served more than 1,200 business clients during his career.
A Pulsed Approach to Treating Cancer
For the first time in a generation the science of PEF (pulsed electrical fields) has changed. Built with the veterinarian and the patient in mind, the VetPulse 2000 is the first of its kind in the world. With hundreds of successful treatments since March 2022, the VetPulse 2000 is now the standard for electrochemotherapy. The VetPulse 2000 is designed for use in veterinary medicine to treat dozens of indications in both small animal and equine medicine.
Business Model
Direct device and electrode sales to hospitals and clinics and international distribution with Patterson Veterinary, a $4.1B veterinary distribution channel.
Device Price
$34,900 – 65% margin
Disposable Costs per Procedure
$150 – 90% margin
LifePulse VetPulse 2000 is the product of more than 15 patents and $35M of R&D over two decades.
The VetPulse 2000 provides effective treatment of tumors as a part of adjuvant, neoadjuvant, or palliative care in horses, dogs, cats, exotics and marine life. Dr Richard Heller and Dr Mark Jaroszeski, the leading scientists in the field, have spent the last three decades perfecting PEF technology. The result is a medical device like nothing that has ever been produced. Able to detect tissue impedance feedback in real time and using less than half the energy of any other device, the VetPulse 2000 is the only US engineered and manufactured device of its kind. We created our device with the end user in mind, making it simple to use and giving the practitioner assurance of delivery, reduced risk of healthy tissue damage and the peace of mind knowing you are using the most advanced, safe and effective method for treatment available.